ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)

BACKGROUND: ARID1A (AT-rich interactive domain containing protein 1A) loss-of-function mutations have been reported in gynecological cancers, including rarer subtypes such as clear cell carcinoma. Preclinical studies indicate that ARID1A mutant cancers display sensitivity to ATR inhibition while tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Susana, Stewart, James, Porta, Nuria, Toms, Christy, Leary, Alexandra, Lheureux, Stephanie, Khalique, Saira, Tai, Jeremy, Attygalle, Ayoma, Vroobel, Katherine, Lord, Christopher J, Natrajan, Rachael, Bliss, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573414/
https://www.ncbi.nlm.nih.gov/pubmed/34518240
http://dx.doi.org/10.1136/ijgc-2021-002973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573414/
https://www.ncbi.nlm.nih.gov/pubmed/34518240
http://dx.doi.org/10.1136/ijgc-2021-002973

Ejemplares similares